RAPP (Rapport Therapeutics) Current Accrued Expense: $5.65 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.06
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Current Accrued Expense?

Rapport Therapeutics RAPP -4.12% 14 Current Accrued Expense is $5.65 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Rapport Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $5.65 Mil.

Rapport Therapeutics's quarterly Current Accrued Expense increased from Sep. 2025 ($3.56 Mil) to Dec. 2025 ($4.98 Mil) and increased from Dec. 2025 ($4.98 Mil) to Mar. 2026 ($5.65 Mil).

Rapport Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($3.22 Mil) to Dec. 2024 ($2.37 Mil) but then increased from Dec. 2024 ($2.37 Mil) to Dec. 2025 ($4.98 Mil).

Rapport Therapeutics Current Accrued Expense Related Terms

Rapport Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Current Accrued Expense Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.21 3.22 2.37 4.98

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.14 3.80 3.56 4.98 5.65
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $5.65 Mil mean?
Rapport Therapeutics (RAPP) has a Current Accrued Expense of $5.65 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Current Accrued Expense too high?
Rapport Therapeutics' current Current Accrued Expense is $5.65 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Current Accrued Expense compare to AUPH and PVLA?
Rapport Therapeutics' Current Accrued Expense of $5.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Current Accrued Expense is $5.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Current Accrued Expense of $5.65 Mil. The current Current Accrued Expense is $5.65 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Current Accrued Expense is $5.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.06
Price